Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.
Location: United States, California, Thousand Oaks
Total raised: $285M
Investors 2
| Date | Name | Website |
| 25.05.2024 | 5AM Ventur... | 5amventure... |
| 13.07.2025 | Foresite C... | foresiteca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.03.2025 | Series B | $150M | - |
| 14.02.2024 | Series A | $135M | - |
Mentions in press and media 11
| Date | Title | Description |
| 17.08.2026 | Latigo Nets $346 Million from Public Offering | - |
| 18.03.2025 | Latigo Biotherapeutics Secures $150 Million to Revolutionize Pain Management | In a bold move that could reshape the landscape of pain management, Latigo Biotherapeutics has successfully closed a $150 million Series B financing round. This Thousand Oaks, California-based biotechnology company is on a mission to develo... |
| 17.03.2025 | Latigo Biotherapeutics Closes $150M in Series B | THOUSAND OAKS, CA, Latigo Biotherapeutics, a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, announced it has closed $150 million in a Series B financing. >> Cl... |
| 17.03.2025 | Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic | Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs. The round was led by Blue Owl Capital, with other participants including Deep Track Capital, Ac... |
| 17.03.2025 | Latigo Biotherapeutics: $150 Million (Series B) Raised For Advancing Non-Opioid Pain Therapeutics | Latigo Biotherapeutics, a clinical-stage biotechnology company developing non-opioid pain treatments that target pain at its source, announced it has closed $150 million in a Series B financing. The proceeds from the financing will support ... |
| 17.03.2025 | Latigo Biotherapeutics Closes $150M in Series B Financing | Latigo Biotherapeutics, a Thousand Oaks, CA-based clinical-stage biotechnology company developing non-opioid pain treatments, raised $150M in Series B funding. The round was led by Blue Owl Capital, with participation from Deep Track Capita... |
| 20.02.2024 | Latigo Biotherapeutics: A Pain-Relief Powerhouse Emerges | Latigo Biotherapeutics, a clinical-stage biotechnology company from Thousand Oaks, CA, has secured a whopping $135M in Series A funding. Led by Westlake Village BioPartners, this funding will propel the development of non-opioid pain medici... |
| 14.02.2024 | Latigo Biotherapeutics Raises $135M in Series A Financing | Desmond Padhi, PharmD, Latigo Biotherapeutics interim CEO Latigo Biotherapeutics, a Thousand Oaks, CA-based clinical-stage biotechnology company developing non-opioid pain medicines that target pain at its source, raised $135M in Series A f... |
| 14.02.2024 | Latigo Biotherapeutics Finds $135M | Thousand Oaks-based Latigo Biotherapeutics, a biotherapeutics company developing non-opioid pain medications, says it has raised $135M in a Series A funding round. The funding was led by Westlake Village BioPartners, which originally incuba... |
| - | 💉💰 PatientFi raises $25M to scale BNPL for healthcare 🤝 Venture Deals 🤝 Venture Deals 🤝 Venture Deals 📅 LA Tech Calendar 📙 What We’re Reading | 🔦 Spotlight Irvine-based PatientFi, a “buy now pay later” provider focused on elective medical procedures, just closed a $25M financing led by Questa Capital to scale up the business. Image Source: PatientFi Picture PatientFi as the Klarna ... |
Show more